Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.

(2018) Ulrich Keilholz et al.   JOURNAL OF CLINICAL ONCOLOGY

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

(2018) Robert M. Jotte et al.   JOURNAL OF CLINICAL ONCOLOGY

Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

(2018) Sam S. Chang   JOURNAL OF UROLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

(2018) Toni K Choueiri et al.   LANCET ONCOLOGY

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

(2018) Y -J Bang et al.   ANNALS OF ONCOLOGY

Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

(2018) Jayesh Desai et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

(2018) Fabrice Barlesi et al.   LANCET ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

1OAdvanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC

(2018) G Mazzaschi et al.   ANNALS OF ONCOLOGY

1165PPreliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors

(2018) L Shen et al.   ANNALS OF ONCOLOGY

1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA

(2018) K P Papadopoulos et al.   ANNALS OF ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

(2017) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical applications of PD-L1 bioassays for cancer immunotherapy

(2017) Delong Liu et al.   Journal of Hematology & Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

(2016) Marlon C. Rebelatto et al.   Diagnostic Pathology

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC

(2016) T. Mok et al.   Journal of Thoracic Oncology

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

(2016) M.-J. Ahn et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor

(2016) Rong Deng et al.   mAbs

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

(2016) Rika Fujii et al.   Oncotarget

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual biological effects of the cytokines interleukin-10 and interferon-γ

(2011) Cailin Moira Wilke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IL-18 Induces PD-1-Dependent Immunosuppression in Cancer

(2011) M. Terme et al.   CANCER RESEARCH

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

(2011) A. M. Paterson et al.   JOURNAL OF IMMUNOLOGY

New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas

(2010) D. Fanoni et al.   IMMUNOLOGY LETTERS

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer

(2008) Yu Liu et al.   CLINICAL IMMUNOLOGY

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA